US 7482002
Method of administering and using VEGF inhibitors for the treatment of prostate cancer
granted A61KA61K38/00A61K38/17
Quick answer
US patent 7482002 (Method of administering and using VEGF inhibitors for the treatment of prostate cancer) held by REGENERON PHARMACEUTICALS, INC. expires Mon Jan 22 2029 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- REGENERON PHARMACEUTICALS, INC.
- Grant date
- Tue Jan 27 2009 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jan 22 2029 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 6
- CPC classes
- A61K, A61K38/00, A61K38/17, A61K45/06, A61P